Device Trial Radar · NCT02363842
Trial Comparing SOC +Skin IQ MCM vs SOC for Pressure Ulcer (PU)
Last checked: Nov 20, 2026Latest source record: Aug 14, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
160
Planned (sponsor's estimate)
Start
Apr 2015
Primary completion
Feb 2016
Study completion Feb 2016
Sponsor
- Lead sponsor
- ArjohuntleighNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Magellan Medical Technology Consultants, Inc.
- First posted
- Feb 16, 2015
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a multi-center, prospective, randomized, controlled, clinical study evaluating the effects of microclimate management using Skin IQ™ MCM coverlet placed over commercially available pressure redistribution surfaces compared to standard of care (SOC). The objective of this study is to evaluate if a commercially available pressure redistribution surface when combined with the Skin IQ™ MCM coverlet will significantly reduce pressure ulcer (PU) incidence as compared to use of a commercially available pressure redistribution surface by itself by decreasing the effects of excessive moisture and temperature at the skin and surface interface.
Conditions
- Pressure Ulcer
Interventions
Skin IQ™ MCM CoverletDevice
Test article is the Skin IQ™ MCM, a Class II 510k exempt product. It is an overlay coverlet indicated to be used in conjunction with a pressure redistribution surface in order to aid in the prevention and treatment of skin breakdown and pressure ulcers for patients who require microclimate management of the skin.
Pressure redistribution surfaceOther
Standard of Care (SOC): pressure redistribution surface already in use at the participating institution to manage patients at risk for tissue breakdown
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Pressure Ulcer developmentTime frame: Up to 60 days for incidence of Pressure Ulcer development
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Integris Baptist Medical Center
Oklahoma City, Oklahoma · Recruiting
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.